367 related articles for article (PubMed ID: 19798500)
1. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
2. NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function.
Chambers WH; Bozik ME; Brissette-Storkus SC; Basse P; Redgate E; Watkins S; Boggs SS
Cancer Res; 1996 Aug; 56(15):3516-25. PubMed ID: 8758920
[TBL] [Abstract][Full Text] [Related]
3. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
4. Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen.
Ginzkey C; Eicker S; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn M; Steinmann J; Hamel W
Acta Neurochir (Wien); 2013 Jan; 155(1):51-8; discussion 59. PubMed ID: 23132370
[TBL] [Abstract][Full Text] [Related]
5. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
6. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
7. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
8. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
9. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
Holladay FP; Lopez G; De M; Morantz RA; Wood GW
Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
[TBL] [Abstract][Full Text] [Related]
10. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
Schiltz PM; Gomez GG; Read SB; Kulprathipanja NV; Kruse CA
J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
[TBL] [Abstract][Full Text] [Related]
11. Impaired capacity for upregulation of MHC class II in tumor-associated microglia.
Schartner JM; Hagar AR; Van Handel M; Zhang L; Nadkarni N; Badie B
Glia; 2005 Sep; 51(4):279-85. PubMed ID: 15818597
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
14. Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections.
Gunawardana T; Ahmed KA; Goonewardene K; Popowich S; Kurukulasuriya S; Karunarathna R; Gupta A; Lockerbie B; Foldvari M; Tikoo SK; Willson P; Gomis S
Sci Rep; 2019 Jan; 9(1):341. PubMed ID: 30674918
[TBL] [Abstract][Full Text] [Related]
15. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
16. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
[TBL] [Abstract][Full Text] [Related]
17. Microglial cell responses to fetal ventral mesencephalic tissue grafting and to active and adoptive immunizations.
Shinoda M; Hudson JL; Strömberg I; Hoffer BJ; Moorhead JW; Olson L
Exp Neurol; 1996 Oct; 141(2):173-80. PubMed ID: 8812150
[TBL] [Abstract][Full Text] [Related]
18. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
Geary SM; Lemke CD; Lubaroff DM; Salem AK
Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
[TBL] [Abstract][Full Text] [Related]
20. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
